Bulletin
Investor Alert

Illumina Inc.

NAS: ILMN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Illumina Inc.

After Hours

 --Quotes are delayed by 20 min

Oct 22, 2021, 5:38 p.m.

ILMN
/zigman2/quotes/203509482/composite

$

406.41

Change

-2.74 -0.67%

Volume

Volume 37,471

Quotes are delayed by 20 min

/zigman2/quotes/203509482/composite

Previous close

$ 411.58

$ 409.15

Change

-2.43 -0.59%

Day low

Day high

$403.49

$413.40

Open

52 week low

52 week high

$288.01

$555.77

Open

Company Description

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Valuation

P/E Current

92.31

P/E Ratio (with extraordinary items)

78.31

P/E Ratio (without extraordinary items)

83.48

Price to Sales Ratio

16.91

Price to Book Ratio

11.51

Price to Cash Flow Ratio

50.19

Enterprise Value to EBITDA

68.41

Enterprise Value to Sales

16.42

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

415,256.00

Income Per Employee

84,103.00

Receivables Turnover

6.11

Total Asset Turnover

0.43

Liquidity

Current Ratio

3.60

Quick Ratio

3.30

Cash Ratio

2.79

Profitability

Gross Margin

68.63

Operating Margin

17.91

Pretax Margin

26.43

Net Margin

20.25

Return on Assets

8.80

Return on Equity

14.10

Return on Total Capital

8.86

Return on Invested Capital

10.51

Capital Structure

Total Debt to Total Equity

40.61

Total Debt to Total Capital

28.88

Total Debt to Total Assets

25.13

Long-Term Debt to Equity

28.63

Long-Term Debt to Total Capital

20.36

Officers and Executives

Name Age Officer Since Title
Mr. Francis A. deSouza 48 2013 President
Mr. Robert P. Ragusa 60 2013 Chief Operations Officer
Mr. Sam A. Samad 49 2017 Chief Financial Officer & Senior Vice President
Dr. Alex Aravanis - 2020 Chief Technology Officer & Senior Vice President
Mr. Steve Phillpott - 2020 Chief Information Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/19/2021 Alex Aravanis
SVP, Chief Technology Officer 		173   Disposition at $414.7 per share. 71,743
10/19/2021 Alex Aravanis
SVP, Chief Technology Officer 		154   Disposition at $413.52 per share. 63,682
10/19/2021 Alex Aravanis
SVP, Chief Technology Officer 		1,051   Disposition at $412.28 per share. 433,306
10/19/2021 Alex Aravanis
SVP, Chief Technology Officer 		948   Disposition at $411.38 per share. 389,988
10/19/2021 Alex Aravanis
SVP, Chief Technology Officer 		600   Disposition at $410.42 per share. 246,252
10/12/2021 Alex Aravanis
SVP, Chief Technology Officer 		151   Disposition at $411.22 per share. 62,094
10/12/2021 Alex Aravanis
SVP, Chief Technology Officer 		709   Disposition at $410.52 per share. 291,058
10/12/2021 Alex Aravanis
SVP, Chief Technology Officer 		893   Disposition at $409.48 per share. 365,665
10/12/2021 Alex Aravanis
SVP, Chief Technology Officer 		750   Disposition at $408.33 per share. 306,247
10/12/2021 Alex Aravanis
SVP, Chief Technology Officer 		423   Disposition at $407.29 per share. 172,283
10/05/2021 Joydeep Goswami
SVP Corp Business Development 		115   Derivative/Non-derivative trans. at $387.98 per share. 44,617
09/28/2021 Susan H. Tousi
SVP, Chief Commercial Officer 		100   Disposition at $418.04 per share. 41,804
09/22/2021 Charles E. Dadswell
SVP & General Counsel 		314   Disposition at $436.69 per share. 137,120
08/30/2021 Susan H. Tousi
SVP, Chief Commercial Officer 		300   Disposition at $463.5 per share. 139,050
08/23/2021 Charles E. Dadswell
SVP & General Counsel 		314   Disposition at $489.1 per share. 153,577
08/18/2021 Alex Aravanis
SVP, Chief Technology Officer 		9,949   Derivative/Non-derivative trans. at $510.61 per share. 5,080,058
08/18/2021 Alex Aravanis
SVP, Chief Technology Officer 		21,653   Award at $510.61 per share. 11,056,238
08/04/2021 Susan H. Tousi
SVP, Chief Commercial Officer 		1,000   Disposition at $500 per share. 500,000
07/28/2021 Susan H. Tousi
SVP, Chief Commercial Officer 		300   Disposition at $486.41 per share. 145,923
/news/latest/company/us/ilmn

MarketWatch News on ILMN

  1. PerkinElmer Inc. stock outperforms market despite losses on the day

    5:16 p.m. Oct. 22, 2021

    - MarketWatch Automation

  2. Illumina Inc. stock underperforms Friday when compared to competitors

    5:00 p.m. Oct. 22, 2021

    - MarketWatch Automation

  3. PerkinElmer Inc. stock falls Thursday, underperforms market

    5:16 p.m. Oct. 21, 2021

    - MarketWatch Automation

  4. Illumina Inc. stock falls Thursday, underperforms market

    5:00 p.m. Oct. 21, 2021

    - MarketWatch Automation

  5. PerkinElmer Inc. stock outperforms competitors on strong trading day

    5:17 p.m. Oct. 20, 2021

    - MarketWatch Automation

  6. Illumina Inc. stock underperforms Wednesday when compared to competitors

    5:00 p.m. Oct. 20, 2021

    - MarketWatch Automation

  7. PerkinElmer Inc. stock rises Tuesday, still underperforms market

    5:16 p.m. Oct. 19, 2021

    - MarketWatch Automation

  8. Illumina Inc. stock outperforms market on strong trading day

    5:00 p.m. Oct. 19, 2021

    - MarketWatch Automation

  9. PerkinElmer Inc. stock rises Monday, still underperforms market

    5:17 p.m. Oct. 18, 2021

    - MarketWatch Automation

  10. Illumina Inc. stock rises Monday, still underperforms market

    5:00 p.m. Oct. 18, 2021

    - MarketWatch Automation

  11. The Man Behind Moderna on What’s Next in Biotech

    11:49 p.m. Oct. 15, 2021

    - Barron's Online

  12. PerkinElmer Inc. stock rises Friday, still underperforms market

    5:16 p.m. Oct. 15, 2021

    - MarketWatch Automation

  13. Illumina Inc. stock rises Friday, still underperforms market

    5:00 p.m. Oct. 15, 2021

    - MarketWatch Automation

  14. PerkinElmer Inc. stock rises Thursday, still underperforms market

    5:16 p.m. Oct. 14, 2021

    - MarketWatch Automation

  15. Illumina Inc. stock rises Thursday, still underperforms market

    5:00 p.m. Oct. 14, 2021

    - MarketWatch Automation

  16. PerkinElmer Inc. stock outperforms competitors on strong trading day

    5:16 p.m. Oct. 13, 2021

    - MarketWatch Automation

  17. Illumina Inc. stock rises Wednesday, still underperforms market

    5:00 p.m. Oct. 13, 2021

    - MarketWatch Automation

  18. PerkinElmer Inc. stock underperforms Tuesday when compared to competitors

    5:16 p.m. Oct. 12, 2021

    - MarketWatch Automation

  19. Illumina Inc. stock outperforms market on strong trading day

    5:00 p.m. Oct. 12, 2021

    - MarketWatch Automation

  20. PerkinElmer Inc. stock falls Monday, underperforms market

    5:16 p.m. Oct. 11, 2021

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/ilmn

Other News on ILMN

  2. Polen Capital Focus Growth Portfolio Manager Commentary Q3 2021

    1:52 p.m. Oct. 21, 2021

    - Seeking Alpha

  3. Let Go of These 4 Toxic Stocks Right Away

    9:16 a.m. Oct. 21, 2021

    - Zacks.com

  4. Mitsubishi UFJ Asset Management (UK) Ltd. Buys Amazon. ...

    12:38 p.m. Oct. 19, 2021

    - GuruFocus.com

  5. New Strong Sell Stocks for October 19th

    10:02 a.m. Oct. 19, 2021

    - Zacks.com

  6. Ensemble Capitals' Quarterly Letter - Q3 2021

    12:45 p.m. Oct. 18, 2021

    - Seeking Alpha

  7. Bet On Biopharma - Data, Digitization And Discovery

    3:02 p.m. Oct. 15, 2021

    - Seeking Alpha

  9. Illumina names Bob Ragusa as CEO of Grail

    2:40 a.m. Oct. 15, 2021

    - Seeking Alpha

  10. IBB: Healthcare Dashboard For October

    8:24 p.m. Oct. 14, 2021

    - Seeking Alpha

  13. 3 COVID Stocks That Can Turn $1,000 Into $10,000

    4:00 p.m. Oct. 12, 2021

    - Motley Fool

  15. Regulatory Hurdles Block a Cancer Miracle

    1:35 p.m. Oct. 8, 2021

    - Allysia Finley

  17. Ipswich Investment Management Co., Inc. Buys Salesforce. ...

    12:38 p.m. Oct. 7, 2021

    - GuruFocus.com

  18. Why Shares of Ilumina Slumped 11.3% in September

    6:26 p.m. Oct. 6, 2021

    - Motley Fool

  20. Here's Why You Should Hold on to Illumina (ILMN) for Now

    11:01 a.m. Oct. 5, 2021

    - Zacks.com

  21. Loading more headlines...

At a Glance

Illumina, Inc.

5200 Illumina Way

San Diego, California 92122

Phone

1 8582024500

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

$3.24B

Net Income

$656.00M

Employees

7,800

Annual Report for ILMN

/news/pressrelease/company/us/ilmn

Press Releases on ILMN

  19. Illumina to Webcast Upcoming Investor Conference

    6:30 p.m. July 28, 2021

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.